Business
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base
About this update from Maravai Lifesciences Holdings, Inc.
[{"type":"text","content":"Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue from high-volume CleanCap® for commercialized vaccine programs, grew 5% year-over-year Net Loss Reduction, Positive Adjusted EBITDA and Positive Free Cash Flow expected by second half 2026 SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2025, together with other business updates. Quarterly Results and Recent Highlights: Quarterly revenue of $47.4 million, Net loss of $(69.8) million (including a goodwill impairment of $30.4 million), and Adjusted EBITDA of $(10.4) million;Appointed Bernd Brust as new Chief Executive Officer (CEO) and member of its board of directors, and Raj Asarpota as Chief Financial Officer (CFO), to accelerate Company’s innovation, execution, and financial performance;Expanded CDMO enablement strategy with a new license and supply agreement for CleanCap with Thermo Fisher Scientific; andLaunched mRNA synthesis kit leveraging several of TriLink BioTechnologies high-performing products and simplifying the in vitro transcription (IVT) workflow for researchers worldwide. “Our base revenue, which excludes revenue from high-volume CleanCap, grew 5% in the quarter, led by strong demand for our Cygnus products and services,\" said Bernd Brust, CEO, Maravai LifeSciences. Brust continued, “While we are encouraged by the base business growth, our existing cost structure is built for a larger company than we are today. Since being appointed CEO, the leadership team and I have embarked on a thorough review of the business and have begun implementing actions expected to realize north of $50 million in annualized cost savings comprising of labor, facilities, capex and productivity initiatives to better align our cost structure with operational needs. Some of these actions impact valued colleagues, and we are approaching the process with care and respect, with a focus on minimizing disruption to our customers and putting Maravai on a path to return to profitability. I'm confident in our team's ability to execute...